Game-Changing Therapeutics
for Pets
Affordable Biologics for
Dogs, Cats, and Horses
The prevalence of chronic diseases in animals is on the rise, while treatment options for many of these conditions remain limited and expensive
Get to Know the Drivers of Pexxes
Katharina and Cornelia met during their veterinary studies in Hannover, where they discovered not only a shared passion for horses, but an even deeper enthusiasm for the transformative power of modern veterinary medicine.
Dr. Katharina Böhme, MBA
CEO and Co-founder of Pexxes
Dr. Cornelia Schwennen
COO and Co-founder of Pexxes
High Tech Science
To identify and develop high-affinity binders with exceptional biological activity and developability properties, we carefully select our partners and technologies.
Our antibody discovery campaigns include phage display from both in vivo immunization and species-specific libraries, enabling us to generate diverse, high-affinity binders against the target of interest.
News
June, 2024
Founding of Pexxes GmbH 11th 2024
After several months of highly productive discussions and considerations, Katharina and Cornelia decided to maintain their momentum and "put some wood behind the arrow." They chose the company name Pe...
October, 2024
Entry of Werner as Angel Investor
Pexxes is supported by the visionary biotech leader Werner Lanthaler. With a proven track record of transforming small biotech startups into large-scale businesses, Lanthaler shares the founders' visi...
FAQs
Mission
Leverage latest science and technologies to generate best and affordable biologics, ensuring access to cutting-edge treatments for dogs, cats and horses worldwide
Vision
Make biologics the affordable global standard of care for dogs, cats and horses
We are currently well seed-funded by investors. However, if you are interested in future investment opportunities feel free to reach out.info@pexxes.com
